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Background. We have known that patients with renal insuﬃciency (creatinine level) have increased mortality for coronary artery
disease. In this study, the relationship between admission creatinine level and one year mortality are evaluated in patients with
acute myocardial infarction (AMI). Method. 160 AMI patients (127 men and 33 women with a mean age of 59 ± 13) were enrolled
in the study. Serum creatinine levels were measured within 12 hours of AMI. The patients were divided into two groups according
to admission serum creatinine level. (1) elevated group (serum creatinine > 1.3mg/dL) and (2) normal group (≤1.3 mg/dL). One
year mortality rates were evaluated. Results. Elevated serum creatinine is observed in the 27 patients (16.9%). The mean creatinine
level is 1.78 ± 7 mg/dL in the elevated group and 0.9 ± 0.18 mg/dL in the normal group (P<0.0001). The mortality rate of the
elevated group (n = 7, 25.9%) is higher than that of the normal group (n = 9, 6.8%). A signiﬁcant increase in one year mortality
is also observed (P = 002) 60. Conclusion. The mildly elevated admission serum creatinine levels are markedly increased to one
year mortality in patients with AMI.
1.Introduction
Ischemic heart disease is more prevalent in patients with
renal dysfunction than in the general population [1–4].
Previous studies showed an increased risk of cardiovascular
disease and adverse cardiovascular outcomes in patients with
renal insuﬃciency. End-stage renal disease, in particular, is
strongly associated with the increased rate of cardiovascular
diseases. There were only a few studies, though, that were
focused on analysing the role of mild and moderate renal
dysfunction in patients with acute myocardial infarction
(AMI). Previous studies, such as GUSTO I, GUSTO II, and
TIMI-2, which involved a large number of AMI patients,
failed to evaluate the signiﬁcance of mild and moderate renal
dysfunction in morbidity and mortality [5–7]. A history of
renal insuﬃciency or increased creatinine level on admission
is associated with poor outcomes in patients with acute
coronary syndrome (ACS). Recently, the Global Registry of
Acute Coronary Events (GRACE) registry has proven that
serum creatinine levels at admission are among the most
importantmarkersofhospitalmortalityinpatientswithACS
[8].
While renal failure greatly increases the risk of coronary
disease, there have not been enough studies on the inﬂuence
of mild renal impairment in patients with AMI. Thus, in
this study, we aim to assess the inﬂuence of mildly elevated
creatinine level in patients with AMI on one-year mortality.
2.MaterialsandMethods
We prospectively studied 160 patients (33 female and 127
male) who arrived in our hospital from January 2008 to
July 2009 for acute coronary syndrome, particularly those
with cases of ST and non-ST elevation MI. All patients in
this study were hospitalized within 12 hours from the onset
of MI symptoms and were medically treated. For patients
with ST elevation, MI tissue plasminogen activator (t-PA)
100mgwasusedasaﬁbrinolyticagent.Patientsweredivided2 The Scientiﬁc World Journal
into two groups according to admission serum creatinine
level. The normal range of serum creatinine is between
0.6 and 1.3mg/dL; therefore, the normal serum creatinine
group was described as having ≤1.3mg/dL (normal group)
and the levels >1.3–2.0mg/dL was described as the elevated
serum creatinine group (elevated group). Acute myocardial
infarction (AMI) was diagnosed on the basis of persisting
chest pain associated with ST-segment elevation at two
or more contiguous ECG leads. It was also diagnosed by
analysing the increase in serum creatine kinase level beyond
2-fold normal upper limit. Patients were excluded if they had
been admitted for more than 12 hours, had a case of valvular
heart disease, had creatinine values of >2mg/dL, orhad a
history of heart failure (heart failure with left ventricular
ejection fraction <40%).
Clinical characteristics, such as age, gender, hyperten-
sion, diabetes, and cigarette smoking, were recorded. The
presence of diabetes mellitus (DM) was considered in
patients who were taking oral hypoglycemic agents, insulin
or fasting plasma glucose level >126mg/dL or >200mg/dL
at any time during hospitalisation. History of smoking and
previous AMI was collected through a medical questionnaire
and data from the medical chart.
Renal function was assessed by serum creatinine (Cr)
measurement at admission, and glomerular ﬁltration rate
(GFR) was calculated using the Cockcroft-Gault formula.
Clinical follow-up data were obtained from outpatients’
records or from a trained clinical research secretary who
made telephone contacts with patients on a yearly basis.
Family members of deceased patients were contacted to
ascertaintimeofdeath.Theprimaryendpoint ofthepresent
study was cardiac death at followup.
3.StatisticalAnalysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences (SPSS, Chicago, Ill, USA) version
15.0 software for Windows. The data were presented as
percentages for discrete variables and as means (±SD) for
continuous variables. The diﬀerences in baseline character-
istics were compared using the t-test and χ2 test. Logistic
regression analysis was performed to assess the independent
value of admission creatinine, urea, glucose, and troponin
levels and to estimate GFR on mortality after one-year fol-
lowup (Table 3). A P value <0.05 was considered statistically
signiﬁcant.
4. Results
The present analysis includes a total of 160 patients (33
women and 127 men). Mean age is 59 ± 13. The number of
anterior, inferior, and non-ST-segment elevation MI patients
is 64 (40%), 60 (37.5%), and 36 (22.5%), respectively.
Thirty-one of the patients are diabetic (19.4%). Mean
hospital time of patients is 5 ± 2 days. The demographic and
clinical characteristics of patients are presented in Table 1.
Elevated serum creatinine was observed in the 27 patients
(16.9%). The mean creatinine level was 1.78 ± 7mg/dL in
Table 1: The general characteristics of the study patients.
Age (years) 58.94 ±13,04
Male, n (%) 127 (79.4)
Hypertension, n (%) 38 (23.8)
Serum urea level (mg/dL) 38 ± 16
Serum creatinine level (mg/dL) 1.07 ± 0.46
Diabetes, n (%) 31 (19.4)
Smoking, n (%) 63 (39.4)
Anterior MI, n (%) 64 (40)
Inferior MI, n (%) 60 (37.5)
Non-ST MI, n (%) 36 (22.5)
GFR (mL/min) 87 ± 32
LVEF (%) 46 ± 9.3
MI: myocardial infarction; GFR: glomerular ﬁltration rate; LVEF: left ven-
tricular ejection fraction.
theelevatedgroupand0.9 ±0.18mg/dLinthenormalgroup
(P<0.0001).
Mean GFR was 44 ± 15mL/min in the elevated group
and 96 ± 26mL/min in the normal group (P<0.0001).
The mortality rate of the elevated group (n = 7, 25.9%)
was higher than the normal group (n = 9, 6.8%), and a
signiﬁcant increase in one-year mortality was observed (P =
002). No signiﬁcant diﬀerence was seen between the two
groups in terms of the presence of the classic cardiovascular
risk factors like age, smoking, diabetes mellitus, and high
blood pressure. As far as AMI location is concerned, no
diﬀerence was found between anterior wall, inferior wall,
and non-STMI myocardial infarction. In view of the infarct
localisation, seven of the dead were anterior MI, eight of
them were inferior MI, and only one case was non-ST MI
(P = 0.236). Three of the cases were diabetic, and 13 cases
were nondiabetic. The clinical features of the two groups are
recorded in Table 2.
The subgroup analysis of our study focuses on the age
criterion of individuals. Elders under the age of 65 showed
ureaof33±10mg/dL,50±20mg/dL(P<0.001),creatinine
of 1 ± 0.2mg/dL, 1.24 ± 0.6mg/dL (P = 0.002), and GFR
of 100 ± 28mL/min, 63 ± 23mL/min (P = 0.002). There
w a sn or e p o r t e dd e a t hu n d e ra g e5 0 ,b u tﬁ v ec a s e so fd e a t h
were reported for patients between the age of 50 and 65 and
11 cases of death were reported for patients who were over
65. This shows that mortality rate is higher over the age of
65 (P = 0.002). Based on gender, females account to six
of the deaths while males account for 10 of the deaths. The
diﬀerence was not signiﬁcant statistically (P = 0.079).
In our study, logistic regression analysis was also per-
formed to predict the parameters that are eﬀective on
mortality. The results of these parameters are the following:
creatinine (ß: 9.1, P = 0.002), urea: (ß: 5.6, P = 0.018),
glucose (ß: 4.3, P = 0.036), troponin (ß: 9.0 P = 0.003),
GFR (ß: 11 P = 0.001), and age (ß: 4.8, P = 0.027). These
parameters showed a statistically signiﬁcant impact on one-
year mortality. As shown on the table, the P values and odds
ratioofbothcreatinineandGFRvaluesaremoremeaningful.The Scientiﬁc World Journal 3
Table 2: Comparison of the characteristics of two groups according
to the creatinine level.
Creatinine ≤ 1.3
n: 133
Creatinine > 1.3
n:2 7
P value
Anterior MI, n (%) 58 (36.3%) 6 (3.8%)
Inferior MI, n (%) 44 (27.5%) 16 (10%) 0.032
Non ST MI, n (%) 31 (19.4%) 5 (3.1%)
Diabetes, n (%) 23 (17.3%) 8 (29.6%) 0.139
Age (years) 65 ± 12 68 ± 12 0.094
Hypertension, n
(%) 30 (22.6%) 8 (29.6%) 0.431
Smoking, n (%) 57 (42.9%) 6 (22.2%) 0.058
eGFR (mL/min) 96 ± 26 44 ± 15 <0.0001
Male, n (%) 109 (82%) 18 (66.7%) 0.073
Serum creatinine
level (mg/dL) 0.9 ± 18 1.78 ± 7 <0.0001
CK/MB (ng/mL) 74 ± 69 98 ± 111 0.119
Troponin (ng/mL) 4.1 ± 11 28 ± 1.6 0.551
LVEF (%) 46 ± 94 7 ± 10 0.740
Serum urea level
(mg/dL) 34 ± 11 59 ± 20 <0.0001
One-year mortality 9 (6.8%) 7 (25.9%) 0.002
MI:myocardialinfarction;eGFR:estimatedglomerularﬁltrationrate;LVEF:
left ventricular ejection fraction.
Table 3: Logistic regression analysis of the eﬀect of risk factors on
one-year mortality.
Odds ratio P
Serum creatinine level 9.1 0.002
Serum urea level 5.6 0.018
Admission serum glucose level 4.3 0.036
Troponin 9.0 0.003
GFR 11 0.001
Age 4.8 0.027
GFR: estimated glomerular ﬁltration rate.
5. Discussion
It was previously shown that end-stage renal disease is a
powerfulpredictorofdeath[9].Althoughtheprecisemecha-
nismsoftheinteractionbetweenimpairedrenalfunctionand
coronaryarterydiseasearenotclariﬁed,theserumcreatinine
concentration may be a marker for concomitant cardio-
vascular risk factors, such as diabetes mellitus, systemic
hypertension, and advanced age. However, less severe renal
dysfunction, deﬁned by a reduction in creatinine clearance
or in glomerular ﬁltration rate (GFR) [10, 11], regardless of
the underlying cause, also may lead to a signiﬁcant increase
in mortality after acute coronary syndromes [1, 2, 12–14].
There are multiple possible explanations for higher
mortality associated with chronic kidney disease, such as
speciﬁc vascular disease, combining calciﬁed atherosclerosis
andlarge vessel remodeling or the presenceof left ventricular
hypertrophy, the eﬀect of chronic volume, or pressure over-
load [15–17]. Serum creatinine concentration is considered
to correlate with oxidative stress, endothelial dysfunction,
and progressive atherosclerosis. These biological abnormal-
ities may increase excessive cardiovascular risk. Two factors
may aﬀect this condition. First, the higher level of serum
creatinine may have an inﬂuence on the underlying clinical
pathophysiological mechanisms that can lead to low cardiac
output resulting in decreased renal blood ﬂow, chronic
volume overload, and diastolic left ventricular dysfunction.
Second, the elevated serum creatinine group had a greater
prevalence of multivessel coronary artery disease and a
history of MI [18]. Comorbidities that are often associated
with impaired GFR and elevated creatinine level could also
explain this higher mortality rate after acute MI [16, 17].
While renal failure signiﬁcantly increases coronary risk,
not enough studies have been made on the inﬂuence of
mild renal impairment in patients with AMI and who were
medically treated on long prognosis, especially on one-year
mortality. However, the early stages of kidney failure are
associated with an increase in the amplitude of the pulse and
high renin concentrations, which can lead to hypertrophy
of the left ventricle. In addition, reductions in hemoglobin
levels have been reported even with mild renal failure [19].
An association has also been found between reduction in
GFR and the levels of tumour necrosis factor α,r e a c t i v e
protein C, and ﬁbrinogen, as well as with dyslipidemia and
other biomarkers [20, 21].
Reinecke et al. indicated that long-term mortality
increases with higher creatinine levels, with a signiﬁcant
diﬀerence that starts at a level of 1.3mg/dL and higher [22].
In the GRACE registry, an increase of 1mg/dL in baseline Cr
was associated with a 1,2-fold increase in hospital death risk.
This elevation in Cr levels has been shown to have higher
prognostic value than cardiac enzyme levels at admission,
since present markers of myocardial necrosis are given more
importance than renal function [8].
Al Suwaidi et al. reported that four ACS trial databases,
including all enrolled patients, were assessed to determine
30- and 180-day outcomes. The four trials used include
GlobalUseofStrategiestoOpenOccludedCoronaryArteries
(GUSTO) IIb, GUSTO-III, Platelet Glycoprotein IIb/IIIa
in Unstable Angina: Receptor Suppression Using Integrilin
Therapy (PURSUIT) and Platelet IIb/IIIa Antagonism for
the Reduction of Acute Coronary Syndrome events in a
Global Organisation Network (PARAGON-A). These trials
explained that mild to moderate renal abnormality indepen-
dently predicts death and myocardial infarction in patients
with ACS at 30-day and 6-month followup [1].
In HIJAMI Registry, Yamaguchi et al. showed that in-
hospital mortality of patients with AMI was greater when
the serum creatinine concentration was elevated. This was
true even in patients with successful primary PCI. This
adverse outcome was observed not only in patients with
severe renal dysfunction but also in those with mild renal
dysfunction. In this study, in-hospital mortality of patients
with mild creatinine level was 17.1% (1.2–2.0mg/dL) while
those with normal creatinine level has 3.9% (<1.2mg/dL)
[23]. In addition, Gibson et al. showed that there was a
stepwise increase in mortality among patients with normal,
mild, or severe impaired renal function. In patients with4 The Scientiﬁc World Journal
ST-segment elevation myocardial infarction (STEMI) and
who were treated with ﬁbrinolysis, 30-day mortality was 5%,
9.5%, and 25.1%, respectively (P<0.0001 for trend) [2],
Unlike these studies, we excluded the patients who died in
the hospital and our primary aim was to determine one-year
mortality. The result was 25.9% in the elevated group and
6.8% in the normal group.
We determined that patients with mild renal dysfunction
also had increased one-year mortality rate. Male gender,
hypertension, smoking, infarct localisations, diabetes, left
ventricleejectionfraction(LVEF),andCK-MBlevelwerenot
statistically diﬀerentiated between the normal and elevated
groups. Creatinine, troponin and urea level, GFR, however,
were statistically diﬀerentiated, and results showed that one-
year mortality was greater in the groups with higher serum
creatinine levels (P=0.002). In addition, subgroup analysis
showedhighermortalityintheover65agegroup.InHIJAMI
Registry,though, agewasshownasanindependent predictor
of greater in-hospital mortality [23]. In addition, in Gibson
et al.’s study, in an analysis restricted to patients 65 years old,
a similar stepwise increase in mortality was observed as renal
impairment increased [2] .O u rr e s u l ti sa l m o s ti d e n t i c a lt o
Gibson et al’s observation in patients with AMI. Therefore,
admission creatinine level may be more important in older
patients.
In a new published study, Dohi et al. showed that the
presence of mild renal dysfunction at ACS is associated
with a worse outcome in the long term in patients with
acute coronary syndrome undergoing percutaneous coro-
nary interventions. Long-term outcomes were compared
over a followup period of 1538 ± 707 days [24]. This
result is similar to our data, but our patient group was
diﬀerent because they included non-ST elevation MI and ST
elevation MI patients who were medically treated but did
not undergo primary percutaneous coronary interventions.
Consequently, these two studies clarify that the presence
of mild renal dysfunction at ACS (both non-ST elevation
and ST elevation MI patients treated with ﬁbrinolytic agent
or percutaneous coronary intervention) is associated with a
worse outcome in the long term.
StudyLimitations
First, the number of participants in the study was limited.
Second, because the level of serum creatinine is of limited
value in the early detection stage of renal insuﬃciency
and is inﬂuenced by factors such as age, gender, race, and
lean muscle mass, there may be a claim that the serum
creatinine level is an unreliable tool in estimating renal
insuﬃciency. This limits our study, but our ﬁndings warrant
further investigation regarding the role of renal insuﬃciency
measured by direct GFR in STEMI patients.
6. Conclusion
In this study, we showed that the presence of STEMI and
elevated creatinine on admission is associated with increased
one-year mortality, independent of other conventional risk
factors. This unwanted outcome is observed not only in
patients with severe renal dysfunction but also in patients
withmildrenaldysfunction.Creatininelevelsareacheapand
fast clinical marker that can estimate long-term mortality in
patients with acute coronary syndromes. Thus, AMI patients
with elevated serum creatinine level on admission need close
followup and intensive management for the prevention of
recurrent cardiovascular events.
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